Quantcast
Last updated on April 17, 2014 at 14:57 EDT

Latest TNF inhibitor Stories

2013-04-15 04:20:52

ZURICH-SCHLIEREN, Switzerland, April 15, 2013 /PRNewswire/ -- Covagen today announced the expansion of its senior management team with the appointment of Elias Papatheodorou as chief business officer. He brings 20 years of work experience including 13 years in the life science sector with a track record of fundraising and collaborative agreements. Prior to joining Covagen, Mr. Papatheodorou was senior vice president business development and operations at Medigene where he led the business...

2013-03-25 12:26:51

EXTON, Pa., March 25, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, after approximately two months on the market, 37 percent of U.S. rheumatologists have prescribed Pfizer's Xeljanz (tofacitinib) in an average of three of their rheumatoid arthritis (RA) patients. However, nearly 10 percent of the surveyed rheumatologists do not plan on using Xeljanz until it has been on the market for...

2013-02-20 08:27:57

ATLANTA, Feb. 20, 2013 /PRNewswire/ -- UCB announced today two new regulatory filings with the US Food and Drug Administration (FDA) and with the European Medicines Agency (EMA) to extend the marketing authorization for Cimzia(®) (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA) and for adult patients with active axial spondyloarthritis (axSpA). The regulatory filings for two new indications for certolizumab pegol are now under review by the US...

New Target For Rheumatoid Arthritis Identified By Researchers
2013-01-25 14:50:37

Hospital for Special Surgery Researchers at Hospital for Special Surgery have identified a potential new target for drugs to treat patients with rheumatoid arthritis (RA), a protein known as IRHOM2. The finding could provide an effective and potentially less toxic alternative therapy to tumor necrosis factor-alpha blockers (TNF-blockers), the mainstay of treatment for rheumatoid arthritis, and could help patients who do not respond to this treatment. Efforts to develop drugs that hone in...

2013-01-03 08:25:32

SOUTH SAN FRANCISCO, Calif., Jan. 3, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, will present an update on the company's product portfolio at the J.P. Morgan Healthcare Conference in San Francisco on January 7, 2013 at 1:30pm Pacific time (see webcast details below). In December 2012, Rigel initiated a Phase 1 clinical study of R348, a topical JAK/SYK inhibitor, as a potential...

2012-12-13 08:26:16

SOUTH SAN FRANCISCO, Calif., Dec. 13, 2012 /PRNewswire/ -- AstraZeneca today announced top-line results of OSKIRA-4, a Phase IIb monotherapy study of fostamatinib, the first kinase inhibitor with selectivity for SYK (spleen tyrosine kinase) in development as an oral treatment for rheumatoid arthritis (RA). OSKIRA-4 was a six month study evaluating improvements in signs and symptoms of RA in 280 patients who had never previously used a disease-modifying anti-rheumatic drug (DMARD), were DMARD...

2012-12-05 08:26:49

MOUNTAIN VIEW, Calif., Dec. 5, 2012 /PRNewswire/ -- The challenges inherent in the pharmacological management of rheumatic diseases have stoked huge demand for drug classes with excellent safety and efficacy profiles. While tumor necrosis factor (TNF) inhibitors have greatly enhanced the treatment of these incurable chronic conditions, their unpredictable and inconsistent efficacy as well as their high cost, potential side effects, and uncomfortable mode of delivery (by injection) are driving...

2012-11-27 04:21:13

LEXINGTON, Mass., Nov. 27, 2012 /PRNewswire/ -- Avaxia Biologics, Inc., a privately-held biotechnology company developing oral antibody drugs that act locally within the digestive tract, announced today that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for AVX-470 for the treatment of ulcerative colitis. AVX-470 is an anti-TNF polyclonal antibody and is the first clinical candidate to come from Avaxia's oral antibody platform. The...

2012-11-14 12:27:03

ATLANTA, Nov. 14, 2012 /PRNewswire/ -- UCB announced today results from the RAPID(TM)-PsA study at the American College of Rheumatology's (ACR) 2012 Annual Scientific Meeting in Washington, D.C., U.S. Data presented from this Phase 3 study showed that compared to placebo, certolizumab pegol provided improvements in the signs and symptoms of psoriatic arthritis (PsA) in adult patients with and without prior anti-TNF (tumor necrosis factor) exposure. Patients in this study could have received...

2012-11-13 08:33:42

BRUSSELS, Nov. 13, 2012 /PRNewswire/ -- UCB announced extensive results from the Phase 3 study - RAPID(TM)-axSpA - at the American College of Rheumatology's (ACR) 2012 Annual Scientific Meeting in Washington D.C., U.S. RAPID(TM)-axSpA enrolled patients with active axial spondyloarthritis (axSpA), including patients with ankylosing spondylitis (AS) and axSpA without radiographic evidence of AS (non-radiographic axSpA [nr-axSpA]). The study showed that...